FINAL RESULTS OF A MULTICENTRE PHASE II TRIAL EVALUATING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS

被引：0
|
作者：
Samalin, E. [1 ]
Desseigne, F. [2 ]
Thezenas, S. [1 ]
Bibeau, F. [1 ]
Viret, F. [3 ]
Mineur, L. [4 ]
Assenat, E. [1 ]
Bleuse, J. [1 ]
Portales, F. [1 ]
Crapez, E. [1 ]
Ychou, M. [1 ]
机构：
[1] CRLC Val Aurelle, Montpellier, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Inst St Catherine, Avignon, France
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [41] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [42] Combination of cetuximab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience.
    Salek, T.
    Sebo, E.
    Mazalova, D.
    Chovanec, J.
    Stresko, M.
    Thomkova, A.
    Andrasina, I.
    Barilla, R.
    Hlavata, Z.
    Mego, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [43] Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)
    Samalin, E.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Laurent-Puig, P.
    Ychou, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S418 - S418
  • [44] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Cetuximab (CTX) in first-line treatment of elderly patients with metastatic colorectal cancer (mCRC), KRAS wild type: French multicentre prospective community-based registry and results.
    Mineur, Laurent
    Francois, Eric
    Phelip, Jean Marc
    Guimbaud, Rosine
    Plassot, Carine
    Smith, Denis Michel
    Miglianico, Laurent
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment?
    Omrcen, T.
    Katic, A.
    Tomic, S.
    Eterovic, D.
    Vrdoljak, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] A phase III comparison of FOLFOXIRI to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC)
    Masi, G.
    Brunetti, I
    Murr, R.
    Benedetti, G.
    Evangelista, W.
    Picone, V
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 22 - 23
  • [48] A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
    Chiritescu, G.
    Dumon, K.
    Macarulla Mercade, T.
    Lang, I.
    Santos Vivas, C.
    Papai, Z.
    Janssens, J.
    Hendrickx, K.
    Pracht, M.
    Van den Eynde, M.
    Taieb, J.
    Moons, V.
    Geboes, K.
    Van Laethem, J.
    Greil, R.
    Cervantes, A.
    Vergauwe, P.
    Ferrante, M.
    Vanderstraeten, E.
    Fridrik, M.
    Woell, E.
    Limon, M.
    Rivera, F.
    Sagaert, X.
    Tejpar, S.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] First-line panitumumab combined with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): data from a phase II, single-arm, multicentre study (20060314)
    Karthaus, M.
    Greil, R.
    Mineur, L.
    Letocha, H.
    Thaler, J.
    Hofheinz, R.
    Fernebro, E.
    Gamelin, E.
    DeCosta, L.
    Koehne, C.-H.
    ONKOLOGIE, 2010, 33 : 62 - 62
  • [50] A phase I/II study of cetuximab (cet) in combination with S-1 and oxaliplatin (SOX) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-06).
    Tsuji, Akihito
    Sunakawa, Yu
    Denda, Tadamichi
    Takinishi, Yasutaka
    Kotaka, Masahito
    Tanioka, Hiroaki
    Shimada, Ken
    Kochi, Mitsugu
    Watanabe, Takanori
    Nakamura, Masato
    Ueda, Hiroto
    Inukai, Michio
    Masuishi, Toshiki
    Tani, Satoshi
    Negoro, Yuji
    Okuno, Tatsuya
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345